CYP2C9 is a principal low-affinity phenacetin O-deethylase: Fluvoxamine is not a specific CYP1A2 inhibitor (multiple letters)

Drug Metabolism and Disposition

Volumn 27, Issue 12, 1999, Pages 1519-1522

  Venkatakrishnan, Karthik ^a   Von Moltke, Lisa L ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PHENACETIN O DEETHYLASE;

DEMETHYLATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROXYLATION; INHIBITION KINETICS; LETTER; LIVER MICROSOME; METABOLISM; METABOLITE; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; MICROSOMES, LIVER; OXIDOREDUCTASES; PHENACETIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY;

EID: 0032751543     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. Bourné M, Meunier V, Berger Y and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
2. Brøsen K, Skjelbo E. Rasmussen BB, Poulsen HE and Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214.
3. Eagling VA, Tjia JF and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
4. Hemeryck A, De Vriendt C and Belpaire FM (1999) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 54:947-51.
5. Kobayashi K, Nakajina M, Oshima K, Shimada N, Yokoi T and Chiba K (1999) Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 27:860-865.
6. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
7. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ and Tsutsui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693.
8. Rasmussen BB, Nielsen TL and Brøsen K (1998) Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur J Clin Pharmacol 54:735-40.
9. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D and Shader RI (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin parahydroxylation. Br J Clin Pharmacol 44:495-498.
10. Venkatakrishnan K, von Moltke LL and Greenblatt DJ (1998) Human cytochromes P450 mediating phenacetin O-deethylation in vitro: Validation of the high-affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502-1507.
11. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS and Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131.
12. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudehadker L, Fogelman SM, Harmatz JS and Shader RI (1996a) Phenacetin 0-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacol 128:398-407.
13. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Wright CE. Harmatz JS and Shader RI (1997) Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacol 132:402-407.
14. von Moltke LL, Greenblatt DJ, Grassi JG, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS and Shader RI (1999) Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 46:839-849.
15. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI (1996b) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.